| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Anticancer activity of seaweeds
|
Gutiérrez-Rodríguez, Anllely G.
|
|
2018
|
23 |
2 |
p. 434-447
|
artikel
|
| 2 |
Biochemical marker discovery, testing and evaluation for facilitating OA drug discovery and development
|
Bay-Jensen, Anne-Christine
|
|
2018
|
23 |
2 |
p. 349-358
|
artikel
|
| 3 |
Computational drug repositioning for rare diseases in the era of precision medicine
|
Delavan, Brian
|
|
2018
|
23 |
2 |
p. 382-394
|
artikel
|
| 4 |
Contents page 2
|
|
|
2018
|
23 |
2 |
p. ii
|
artikel
|
| 5 |
Contents page 1
|
|
|
2018
|
23 |
2 |
p. i
|
artikel
|
| 6 |
Dendrimer nanohybrid carrier systems: an expanding horizon for targeted drug and gene delivery
|
Kesharwani, Prashant
|
|
2018
|
23 |
2 |
p. 300-314
|
artikel
|
| 7 |
Discovery of hidden allosteric sites as novel targets for allosteric drug design
|
Lu, Shaoyong
|
|
2018
|
23 |
2 |
p. 359-365
|
artikel
|
| 8 |
Fishing anti(lymph)angiogenic drugs with zebrafish
|
García-Caballero, Melissa
|
|
2018
|
23 |
2 |
p. 366-374
|
artikel
|
| 9 |
Galectin-3: mediator of microglia responses in injured brain
|
Rahimian, Reza
|
|
2018
|
23 |
2 |
p. 375-381
|
artikel
|
| 10 |
Gemcitabine and glioblastoma: challenges and current perspectives
|
Bastiancich, Chiara
|
|
2018
|
23 |
2 |
p. 416-423
|
artikel
|
| 11 |
Guiding principles of value creation through collaborative innovation in pharmaceutical research
|
Schweizer, Liang
|
|
2018
|
23 |
2 |
p. 213-218
|
artikel
|
| 12 |
Haspin: a promising target for the design of inhibitors as potent anticancer drugs
|
Amoussou, Nathalie Gisèle
|
|
2018
|
23 |
2 |
p. 409-415
|
artikel
|
| 13 |
Interfering peptides targeting protein–protein interactions: the next generation of drugs?
|
Bruzzoni-Giovanelli, Heriberto
|
|
2018
|
23 |
2 |
p. 272-285
|
artikel
|
| 14 |
Market entry, power, pharmacokinetics: what makes a successful drug innovation?
|
Alt, Susanne
|
|
2018
|
23 |
2 |
p. 208-212
|
artikel
|
| 15 |
Marketing authorisation of orphan medicines in Europe from 2000 to 2013
|
Hofer, Matthias P.
|
|
2018
|
23 |
2 |
p. 424-433
|
artikel
|
| 16 |
Medicinal chemistry in drug discovery in big pharma: past, present and future
|
Campbell, Ian B.
|
|
2018
|
23 |
2 |
p. 219-234
|
artikel
|
| 17 |
Mesoporous silica nanoparticles: a smart nanosystem for management of breast cancer
|
Poonia, Neelam
|
|
2018
|
23 |
2 |
p. 315-332
|
artikel
|
| 18 |
Molecular dynamics simulation strategies for designing carbon-nanotube-based targeted drug delivery
|
Al-Qattan, Mohammed N.
|
|
2018
|
23 |
2 |
p. 235-250
|
artikel
|
| 19 |
NCp7: targeting a multitasking protein for next-generation anti-HIV drug development part 1: covalent inhibitors
|
Sancineto, Luca
|
|
2018
|
23 |
2 |
p. 260-271
|
artikel
|
| 20 |
Orodispersible dosage forms: biopharmaceutical improvements and regulatory requirements
|
Cilurzo, Francesco
|
|
2018
|
23 |
2 |
p. 251-259
|
artikel
|
| 21 |
Patient-centered clinical trials
|
Chaudhuri, Shomesh E.
|
|
2018
|
23 |
2 |
p. 395-401
|
artikel
|
| 22 |
Phenytoin repositioned in wound healing: clinical experience spanning 60 years
|
Keppel Hesselink, Jan M.
|
|
2018
|
23 |
2 |
p. 402-408
|
artikel
|
| 23 |
Recent advances in bacteriophage-based methods for bacteria detection
|
Richter, Łukasz
|
|
2018
|
23 |
2 |
p. 448-455
|
artikel
|
| 24 |
The ambivalent place of ethics in European regulatory documents
|
Bernabe, R.D.L.C.
|
|
2018
|
23 |
2 |
p. 205-207
|
artikel
|
| 25 |
The role of fMRI in drug development
|
Carmichael, Owen
|
|
2018
|
23 |
2 |
p. 333-348
|
artikel
|
| 26 |
What is precise pathophysiology in development of hypertension in pregnancy? Precision medicine requires precise physiology and pathophysiology
|
Gao, Qinqin
|
|
2018
|
23 |
2 |
p. 286-299
|
artikel
|
Tijdschrift beschrijving